en · de · es · fr · pt
tb-500-notes.peptides6823.com › Info › Thymosin Beta-4 Fragment Overview — Evidence Review

Thymosin Beta-4 Fragment Overview — Evidence Review

By Editorial Desk · published 2026-07-12 · last reviewed 2026-08-01 · Info

This is a working overview of actin binding, written for readers who want more than a one-paragraph summary but less than a textbook.

Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.

Thymosin Beta-4 Fragment Overview

TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.

Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.

The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.

Identity and Reported Background

Discussion of the compound frequently appears alongside other short peptides described as fragments of larger proteins. That grouping is convenient but can be misleading, because fragment length, charge, and modification state determine how a peptide behaves in solution and in any experimental system. A seven-residue acetylated peptide and a full-length protein differ in mass by roughly an order of magnitude, and they cannot be assumed to share distribution or binding properties. Precision about which molecule is under discussion is the single most useful step when reading such material.

TB-500 is a shorthand label used in supplier catalogs and online discussion for a short synthetic peptide described as a fragment of thymosin beta-4. Most product listings present it as the N-terminally acetylated heptapeptide Ac-LKKTETQ, a sequence corresponding to the actin-binding region of the parent protein. The name is not a formal chemical designation and does not appear in standard nomenclature systems. Because labeling practices vary between vendors, two products sold under the same name may not contain the same molecule, and the stated sequence should be treated as a claim rather than a fixed definition.

Thymosin beta-4 is a naturally occurring protein of 43 amino acids found in most mammalian cells, where it binds actin monomers and influences filament dynamics. It was first isolated from thymus tissue in the early 1980s, and its actin-binding activity was later mapped to a short region near the N-terminus. The synthetic fragment sold as TB-500 was designed to reproduce that region rather than the full protein. Whether a short fragment reproduces the behavior of the intact molecule remains an open question, since the parent protein carries additional structural elements outside the binding region.

Tb-500 at a glance

PropertyValueNotes
AppearanceWhite to off-white powderLyophilized solid as supplied
Water solubilitySolubleDissolves in aqueous media
Typical storage temperature-20 °CDry powder, desiccated, protected from light
Typical analytical methodRP-HPLC with mass spectrometryPurity from peak area; mass for identity
Common synonymsTβ4 fragment; thymosin beta-4 fragmentNaming varies by supplier and catalogue

Storage and Analytical Verification

Lyophilized peptide arrives as a dry cake that should stay sealed until use. Reconstitution is generally performed with sterile water or a buffered solution, and the resulting liquid should be handled gently to limit mechanical stress. Repeated freeze-thaw cycles are widely described as harmful to short peptides, so dividing a reconstituted batch into single-use portions is a common practice. Laboratories also record the solvent, concentration, and date of preparation on the vial label to keep later measurements traceable.

Dry powder is commonly held at minus twenty degrees Celsius, with some suppliers recommending lower temperatures for long-term archival storage. Once dissolved, solutions are typically kept cold and protected from light, since aqueous peptide solutions can lose integrity through hydrolysis or oxidation over time. Stability data specific to this fragment are limited in the public literature, and much of the guidance comes from general peptide handling practice rather than from controlled degradation studies. Users therefore treat stated shelf lives as approximate rather than fixed.

Identity and purity are normally assessed with reversed-phase high-performance liquid chromatography, paired with mass spectrometry to confirm molecular mass. A certificate of analysis reports a purity percentage, usually derived from chromatographic peak area, but that figure does not by itself prove a correct sequence or the absence of counterions. Independent verification may include amino acid analysis or peptide mapping. Batch-to-batch variation is a documented concern in the research chemical market, and the gap between a quoted purity value and actual peptide content can be substantial when the material is a salt or retains residual water.

Related pages on this site

Thymosin Beta-4 Fragment Identity

Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.

No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.

TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.

Supporting material

=== Metric ounce === A metric ounce is an approximation of the imperial ounce, US dry ounce, or US fluid ounce. These three customary units vary. However, the metric ounce is usually taken as 25 or 30 ml (0.88 or 1.06 imp fl oz; 0.85 or 1.01 US fl oz) when volume is being measured, or in grams when mass is being measured. The US Food and Drug Administration (FDA) defines the "food labeling ounce" as 30.0 ml (1.06 imp fl oz; 1.01 US fl oz), slightly larger than the 29.6 ml (1.04 imp fl oz; 1.00 US fl oz) fluid ounce. Several Dutch units of measurement have been replaced with informal metric equivalents, including the ons or ounce. It originally meant 1⁄16 of a pound, or a little over 30 g (1.1 oz) depending on which definition of the pound was used, but was redefined as 100 g (3.5 oz) when the country metricated.

Research on PFOA has demonstrated ubiquity, animal-based toxicity, and some associations with human health parameters and potential health effects. Additionally, advances in analytical chemistry in recent years have allowed the routine detection of low- and sub-parts per billion levels of PFOA in a variety of substances. In 2013, Gore-Tex eliminated the use of PFOAs in the manufacture of its weatherproof functional fabrics. Major companies producing PFOA signed with the Global PFOA Stewardship Program with the goal of elimination of PFOA by 2015. Since then it has been eliminated from the production of non-stick materials used in cookware. GenX has been introduced as a replacement for PFOA, but in a 2015 study which tested the effects on rats, GenX caused many of the same health problems as PFOA, but required much higher concentrations. This is because GenX (C3) is a short chain alternative to PFOA. GenX also has a significantly shorter half-life than PFOA so it is not as bio-persistent as PFOA or other long chain perfluorinated chemicals.

=== Sniper: G.R.I.T. – Global Response & Intelligence Team (2023) === When an international terrorist cult threatens global political stability and kidnaps a fellow agent, ace sniper Brandon Beckett and the newly formed Global Response & Intelligence Team (G.R.I.T.) — led by Colonel Stone must travel across the world to Malta, infiltrate the cult, and take out its leader to free Lady Death and stop the global threat.

Beginning in 1986, members of the University Health Center including Presbyterian University Hospital, Falk Clinic, the Pittsburgh Cancer Institute and Eye & Ear Hospital consolidated into the Medical and Health Care Division (MHCD) and led by Detre, became closely linked administratively, although Presbyterian University Hospital remained separate. In 1990, MHCD acquired neighboring Montefiore Hospital which merged with Presbyterian University Hospital to form the "University of Pittsburgh Medical Center" (shortened to UPMC), the first time that name was officially used. UPMC then formed a network of specialty and community hospitals in 1994 named the Tri-State Health System and established a for-profit health insurance division, UPMC Health Plan, which contracted with these hospitals. In 1996, UPMC acquired South Side, Aliquippa and Braddock hospitals. Meanwhile, UPMC began to merge with several of the already affiliated Tri-State hospitals including St. Margaret Memorial, Shadyside, and Passavant hospitals in 1997 and Magee-Womens Hospital in 1998. The acquisition and mergers consolidated the Tri-State Health System into a significant portion of the UPMC health system. Due to the immense growth of the medical center, as well as the university's concerns over financial risks associated with faculty practice in the face of national changes in health care reimbursement, the University of Pittsburgh and UPMC separated in 1998, launching UPMC as an independent nonprofit corporation supporting the university.

Sources: en.wikipedia.org

Notes from published material

Due to their high porosity and large surface area-to-volume ratio, nanofibers are widely used to construct scaffolds for biological applications. Major examples of natural polymers used in scaffold production are collagen, cellulose, silk fibroin, keratin, gelatin and polysaccharides such as chitosan and alginate. Collagen is a natural extracellular component of many connective tissues. Its fibrillary structure, which varies in diameter from 50-500 nm, is important for cell recognition, attachment, proliferation and differentiation. Using type I collagen nanofibers produced via electrospinning, Shih et al. found that the engineered collagen scaffold showed an increase in cell adhesion and decrease in cell migration with increasing fiber diameter. Using silk scaffolds as a guide for growth for bone tissue regeneration, Kim et al. observed complete bone union after 8 weeks and complete healing of defects after 12 weeks whereas the control in which the bone did not have the scaffold displayed limited mending of defects in the same time period. Similarly, keratin, gelatin, chitosan and alginate demonstrate excellent biocompatibility and bioactivity in scaffolds. However, cellular recognition of natural polymers can easily initiate an immune response. Consequently, synthetic polymers such as poly(lactic acid) (PLA), polycaprolactone (PCL), polyurethane (PU), poly(lactic-co-glycolic acid) (PLGA), poly(L-lactide) (PLLA), and poly(ethylene-co-vinylacetate) (PEVA) have been developed as alternatives for integration into scaffolds.

=== Secondary protection === Secondary protection refers to early detection of disease, potentially while still asymptomatic, to allow positive intervention to prevent, delay, or attenuate the symptomatic clinical condition. This includes the following: retinoids (e.g., tretinoin), antioxidants (e.g., topical vitamin C, oral supplements, CoQ10, Lipoic acid), estrogens, growth factors, and cytokines. There are various forms of topical retinoids. Tretinoin, a retinoid, is widely considered to be the most efficacious treatment for photoaging by dermatologists due to consistent evidence from several randomized clinical trials. Retinoids are vitamin A derivatives that bind to retinoic acid receptors (RARs) and retinoid X receptors (RXRs). Binding to these receptors induces a cascade of cellular processes that ultimately lead to increased collagen production and epidermal thickening, reducing the appearance of skin sagging and wrinkling. Tretinoin is also efficacious for the treatment of acne. Adapalene and tazarotene are also third-generation synthetic retinoids that are used for the treatment of acne. Adapalene has not been widely studied or proven for use in photoaging. However, it has been used off-label for that purpose. Tazarotene has been proven to be efficacious in the treatment of photoaging. Retinoid derivatives, known as retinol and retinal, are often used in over-the-counter cosmeceutical products for anti-aging purposes. The form of and retinal are metabolized in the skin to retinoic acid, which can then act on the RARs and RXRs.

== Availability and purity == Iodine-125 is commercially available in dilute NaOH solution as 125I-iodide (or the hypohalite sodium hypoiodite, NaIO). The radioactive concentration lies at 4 to 11 GBq/mL and the specific radioactivity is > 75 GBq/μmol (7.5 × 1016 Bq/mol). The chemical and radiochemical purity is high. The radionuclidic purity is also high; some 126I (t1/2 = 12.93 d) is unavoidable due to the neutron capture noted above. The 126I tolerable content (which is set by the unwanted isotope interfering with dose calculations in brachytherapy) lies at about 0.2 atom % (atom fraction) of the total iodine (the rest being 125I).

Sources: en.wikipedia.org

Frequently asked questions

What is TB-500?

TB-500 is a name used for a short synthetic peptide fragment taken from the actin-binding region of thymosin beta-4. Material sold under this label is usually a lyophilized powder supplied for laboratory research rather than a licensed medicine. The commonly cited sequence is LKKTETQ.

How does it differ from full thymosin beta-4?

The parent protein contains forty-three amino acids, while the fragment carries only a short motif from one region. The fragment can interact with actin in vitro, but it does not include the rest of the protein structure. Whether the shorter molecule behaves the same way in living systems is not settled.

Is human evidence available?

Published controlled human studies are scarce, and most activity reports come from cell culture or animal models. Reviews often describe the evidence base as limited and methodologically uneven. Open questions include the relationship between route, dose, and measured outcomes.

What is TB-500 made of?

Most listings describe it as a short acetylated peptide with the sequence Ac-LKKTETQ, presented as a region of thymosin beta-4. The label is a trade-style name rather than a standardized chemical name, so the exact content of a given vial depends on the supplier.

Network